e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 47

Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer

Mark Thalgott; Thomas Horn; Matthias Heck; Tobias Maurer; Matthias Eiber; Margitta Retz; Michael Autenrieth; Kathleen Herkommer · 2014 · Journal of Hematology & Oncology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: Patients with locally advanced and high-risk prostate cancer (LAPC) are prone to experience biochemical recurrence despite radical prostatectomy (RP). We evaluated feasibility, safety and activity of a neoadjuvant chemohormonal therapy (NCHT) with 3-weekly full dose docetaxel and complete androgen blockade (CAB) in locally advanced and high-risk prostate cancer patients (LAPC) undergoing RP. METHODS: Patients (n = 30) were selected by Kattans' preoperative score and received trimestral buserelin 9,45 mg, bicalutamide 50 mg/day and 3 cycles docetaxel (75 mg/m²) followed by RP. Prima

Abstract by Mark Thalgott; Thomas Horn; Matthias Heck; Tobias Maurer; Matthias Eiber; Margitta Retz; Michael Autenrieth; Kathleen Herkommer, Journal of Hematology & Oncology (2014) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1186/1756-8722-7-20